Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,629 | -2,938 | -328 | -69 | -356 |
| Depreciation Amortization | 108 | 79 | 50 | 25 | 105 |
| Accounts receivable | 651 | 506 | 354 | 336 | 539 |
| Accounts payable and accrued liabilities | -381 | -365 | -111 | -433 | -120 |
| Other Working Capital | 118 | 106 | -1 | -28 | 833 |
| Other Operating Activity | 311 | 1,572 | -104 | 53 | -450 |
| Operating Cash Flow | $-1,822 | $-1,040 | $-140 | $-117 | $552 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -149 | -149 | -15 | 0 | -54 |
| Purchase Of Investment | -321 | -296 | -13 | -14 | -512 |
| Sale Of Investment | 26 | 27 | N/A | N/A | N/A |
| Other Investing Activity | -1,350 | 49 | 20 | 9 | 115 |
| Investing Cash Flow | $-1,794 | $-369 | $-8 | $-5 | $-451 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | N/A | -34 |
| Common Stock Issued | 5,750 | 5,750 | N/A | N/A | 150 |
| Other Financing Activity | 525 | -7 | -4 | -2 | -8 |
| Financing Cash Flow | $6,275 | $5,743 | $-4 | $-2 | $108 |
| Exchange Rate Effect | -260 | -307 | -208 | -22 | -215 |
| Beginning Cash Position | 2,119 | 2,119 | 2,119 | 2,119 | 2,124 |
| End Cash Position | 4,518 | 6,147 | 1,759 | 1,973 | 2,119 |
| Net Cash Flow | $2,399 | $4,028 | $-360 | $-146 | $-5 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,822 | -1,040 | -140 | -117 | 552 |
| Capital Expenditure | -149 | -149 | -15 | 0 | -54 |
| Free Cash Flow | -1,972 | -1,188 | -155 | -117 | 498 |